Drug Type Small molecule drug |
Synonyms Lodienset, 로디엔셋정 |
Target |
Action antagonists, inhibitors, blockers |
Mechanism AT1R antagonists(Angiotensin II Receptor Type 1 antagonists), NCC inhibitors(Thiazide-sensitive sodium-chloride cotransporter inhibitors), VDCCs blockers(Voltage-gated calcium channel blockers) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date South Korea (28 Oct 2025), |
Regulation- |
Molecular FormulaC20H25ClN2O5 |
InChIKeyHTIQEAQVCYTUBX-UHFFFAOYSA-N |
CAS Registry88150-42-9 |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Essential Hypertension | South Korea | 28 Oct 2025 |





